William D. Young Joins NanoString Technologies as Executive Chairman of the Board
Mr. Young has a long record of leadership in the life sciences industry. He joins NanoString after serving as Chairman and Chief Executive Officer of Monogram Biosciences, Inc., a pioneer in the field of personalized medicine. Prior to Monogram, he was Chief Operating Officer of Genentech. Before Genentech, he served in positions of increasing responsibility at Eli Lilly. Mr. Young currently serves as the Chairman of the Board of Biogen Idec, Inc., is a Director and Chairman Emeritus for BayBio, and is a Director at Theravance, Inc.
“I am excited about my new role as Executive Chairman of NanoString because I believe the company’s technology holds great promise for breaking down some of the barriers that still exist in making personalized medicine a reality,” said Mr. Young. “I look forward to helping the company develop the next phase of its commercialization strategy, which includes expanding the applications for the technology into molecular diagnostics.”
Mr. Young received a B.S. in Chemical Engineering from Purdue University, an M.B.A. from Indiana University, and an honorary Doctorate in Engineering from Purdue University. He is an elected member of the National Academy of Engineering for his innovative work in bioprocesses.
“Bill’s unique experience in clinical diagnostics and biotechnology is an ideal combination for NanoString as the company explores new markets for its nCounter molecular analysis system,” said Nicholas Galakatos, Ph.D., Managing Director of Clarus Ventures and member of the NanoString Board of Directors. “His leadership, domain expertise, and strategic thinking will be extremely valuable for NanoString as it seeks to create value in multiple market segments.”
About NanoString Technologies, Inc.
NanoString Technologies is a privately held life sciences company marketing a complete solution for detecting and counting large sets of target molecules in biological samples. The company’s nCounter™ Analysis System is the first and only technology platform to deliver highly multiplexed, direct profiling of individual molecules in a single reaction without amplification. The first application for the nCounter Analysis System addresses an unmet need in targeted gene expression analysis by offering a cost-effective way to easily profile hundreds of gene transcripts simultaneously with high sensitivity and precision. The company’s technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. NanoString is also developing the technology for use in molecular diagnostics. For more information, please visit www.nanostring.com.
Download Press Release